The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ibrutinib + Rituximab vs. FCR

386 views
October 4, 2019
Comments 0
Login to view comments. Click here to Login